On Wednesday an FDA advisory panel will consider an expanded indication for Amarin Pharmaceuticals’ Vascepa, an EPA fish oil product currently indicated only for people with severe hypertriglyceridemia (>500 mg/dl). The new indication would greatly expand the patient population eligible to receive Vascepa, from the relatively few people with severe hypertriglyceridemia to the many millions…
Why The FDA Probably Won’t Approve An Expanded Indication For Amarin’s Vascepa
October 14, 2013 by Leave a Comment
WSJ Article Fails To Raise Key Questions About Cardiovascular Risk In Children
April 30, 2013 by Leave a Comment
There’s probably no greater public health issue than the long-term consequences of the childhood obesity epidemic. So the Wall Street Journal should be commended for digging into some of the important science behind this problem in a feature article in today’s paper. The author, Ron Winslow, is widely regarded as the best working journalist who…
Recent Comments